Loading
AIM ImmunoTech Inc. Stock: price and insider trades · United States
1 insider bought €12k of shares over the last 90 days, the latest filed 18 Sept 2026.
AIM ImmunoTech Inc.: what insiders have been doing
AIM ImmunoTech Inc., classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). The last twelve months, up to 18 October 2026, brought 7 filings signed by 2 insiders.
Every open-market trade in the period is a purchase: 4 purchases worth €12k, from 1 insider, and not a single sale. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. On the buying side, the filings list 1 chief executive among the declarants. Biggest ticket of the year: €4,355, bought by Equels Thomas K. and made public on 18 September 2026 (0.060% of market cap).
Compared with its exchange (5,811 companies, median 19 filings), a count of 7 filings is below the norm. Since 2021, the database holds 37 purchases and 1 sale by insiders of the company. The 10-K for the year ended 31 December 2025 shows 88,000 USD of revenue and -14.0 m USD of net income.
The clock since the last published purchase (18 September 2026) now reads 30 days. Typically, a trade is published a median of 1 day after it takes place. US insiders must file a Form 4 within two business days of a trade.
In the same sector, recent insider purchases at Cooper Companies, Inc. and Anixa Biosciences Inc also feature in our signals. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
77
Thresholds
n/a
Buy Volume
€462,188
37 ops. · all time
Sell Volume
€854
1 ops. · all time
Who traded when
BuySaleThomas K. Equels15 buys
Stewart Appelrouth2 buys
William M. Mitchell1 buy1 sale
Peter W. Rodino III1 buy
Ted D. Kellner1 buy
Since the insiders bought
- -95.9%Entry US$9.84 · Close at T+365 US$0.40
- -92.3%Entry US$6.79 · Close at T+365 US$0.52
- -92.3%Entry US$6.79 · Close at T+365 US$0.52
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$0.17
Analyst consensus
2 analysts1.50/5
US$1.50Target US$4.25(+2401%)US$7.00
Income statement
RevenueUS$88k
Gross profit-US$40k-45% margin
EBITDA-US$12.9M-14700% margin
Net income-US$14M-15861.4% margin
Valuation
PER (forward)-0.5x
P/Book0.6x
Beta1.27
Balance sheet & cash
Market capUS$6.8M
Total debtUS$4.9M
Free Cash Flow-US$11.3M
Debt / Equity51%
Profitability & ownership
ROE-2382.3%
ROA-82.6%
% insiders0.5%
% institutions2.9%
Last declaration on 18 September 2026
Declarations77 total
24,000 shares@ US$0.2080.060% mcap0.8% of flowCommon StockSEC:0001493152-26-043246:0
Canonical exit: 16 Dec 2026 (T+90)
11,000 shares@ US$0.210.028% mcap0.4% of flowCommon StockSEC:0001493152-26-043073:0
Canonical exit: 15 Dec 2026 (T+90)
22,000 shares@ US$0.2210.058% mcap0.8% of flowCommon StockSEC:0001493152-26-042848:0
Canonical exit: 14 Dec 2026 (T+90)
5,900 shares@ US$0.2190.015% mcap0.2% of flowCommon StockSEC:0001493152-26-042754:0
Canonical exit: 13 Dec 2026 (T+90)
25,000 shares0Common stockSEC:0001493152-26-010334:0
25,000 shares0Common StockSEC:0001493152-26-010332:0
2,800 shares@ US$1.2328.6% of flowCommon StockSEC:0001493152-26-005620:0
107 shares@ US$7.6970.1% of flowCommon StockSEC:0001641172-25-015207:0
Canonical exit: 11 Sept 2025 (T+90)
103 shares@ US$8.700.1% of flowCommon StockSEC:0001641172-25-015005:0
Canonical exit: 10 Sept 2025 (T+90)
196,851 shares@ US$0.02549.9% of flowCommon StockSEC:0001641172-25-005862:0
Canonical exit: 10 Jul 2025 (T+90)
1,968,504 shares@ US$0.02548.1% of flowCommon StockSEC:0001641172-25-005861:0
Canonical exit: 10 Jul 2025 (T+90)
1,968,504 shares@ US$0.0254100.0% of flowCommon StockSEC:0001641172-25-005860:0
Canonical exit: 10 Jul 2025 (T+90)
41,000 shares@ US$0.0630.4% of flowCommon StockSEC:0001641172-25-002977:0
Canonical exit: 3 Jul 2025 (T+90)
500 shares@ US$0.0870.0% of flowCommon StockSEC:0001641172-25-002827:0
Canonical exit: 3 Jul 2025 (T+90)
44,899 shares@ US$0.1169.0% of flowCommon StockSEC:0001493152-25-010819:0
44,899 shares@ US$0.11610.6% of flowCommon StockSEC:0001493152-25-010821:0
44,899 shares@ US$0.11646.9% of flowCommon StockSEC:0001493152-25-010818:0
50,000 shares@ US$0.13461.1% of flowCommon StockSEC:0001493152-25-009338:0
Canonical exit: 3 Jun 2025 (T+90)
44,000 shares@ US$0.1150.9% of flowCommon StockSEC:0001493152-25-009164:0
Canonical exit: 2 Jun 2025 (T+90)
19,290 shares@ US$0.13524.5% of flowCommon StockSEC:0001493152-25-009020:0
38,580 shares@ US$0.13511.1% of flowCommon StockSEC:0001493152-25-009015:0
83,334 shares@ US$0.121.7% of flowCommon StockSEC:0001493152-25-009003:0
Canonical exit: 2 Jun 2025 (T+90)
38,580 shares@ US$0.1359.4% of flowCommon StockSEC:0001493152-25-009013:0
43,330 shares@ US$0.12029.3% of flowCommon StockSEC:0001493152-25-007578:0
43,330 shares@ US$0.120211.0% of flowCommon StockSEC:0001493152-25-007579:0
25 of 77 declarations
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is a U.S.-based immuno-pharma company listed on the NYSE American market in the United States, and for investor context it sits within the broader U.S. exchange universe that includes NYSE and NASDAQ. The company is headquartered in Ocala, Florida, and is focused on research and clinical development of immunomodulatory therapeutics for cancer, viral diseases, and immune-disorder indications. Its lead asset is Ampligen® (rintatolimod), which AIM describes as a broad-spectrum immunomodulator. ([aimimmuno.com](https://aimimmuno.com/about/?utm_source=openai))
AIM’s business profile is that of a development-stage biotech rather than a diversified commercial pharmaceutical company. Historically, the company has built its valuation story around advancing a lead platform through clinical trials, securing orphan-drug and other regulatory designations, and expanding the evidence base across multiple indications. That model creates leverage to positive clinical readouts, but it also means the investment case is highly dependent on trial execution, funding access, and regulatory progress. Recent filings and company releases show a strong strategic emphasis on pancreatic cancer, while Ampligen is also being explored in other solid tumors and in certain viral/post-viral conditions. ([aimimmuno.com](https://aimimmuno.com/about/?utm_source=openai))
Read moreShow less
The most important current program is Ampligen in late-stage pancreatic cancer, including the DURIPANC study combining Ampligen with AstraZeneca’s Imfinzi® (durvalumab). AIM reported positive interim safety and efficacy updates in 2025 and, in April 2026, said it was entering a pivotal value-inflection phase with plans for a Phase 3 study. The company has also highlighted orphan-drug designations for pancreatic cancer in both the United States and Europe, and said it plans to seek similar status in Japan. ([aimimmuno.com](https://aimimmuno.com/aim-immunotech-posts-virtual-investor-key-opinion-leader-segment-spotlighting-ampligen-breakthrough-data-in-pancreatic-cancer/?utm_source=openai))
From a product perspective, AIM is centered almost entirely on Ampligen, rather than on a broad marketed portfolio. The company has described use cases in pancreatic cancer, other solid tumors, severe chronic fatigue syndrome, and COVID-related or post-COVID conditions, including ME/CFS. It has also referenced an early-access program in the Netherlands at Erasmus Medical Center and clinical activity in international research settings. That geographic footprint gives the company a modest global reach, but its operational center remains the United States, with headquarters in Florida. ([aimimmuno.com](https://aimimmuno.com/about/?utm_source=openai))
Recent corporate milestones include third-quarter 2025 financial results, continued progress in pancreatic cancer development, a March 2026 agreement with Thermo Fisher Scientific’s PPD unit to help design the anticipated Phase 3 trial, a rights offering announced in early 2026, and a virtual investor presentation released in May 2026 highlighting updated pancreatic cancer data. For French-speaking investors, AIM should be viewed as a highly speculative micro-cap biotech story, where the upside is tied to clinical data and regulatory milestones, while dilution risk and binary trial outcomes remain central considerations. ([aimimmuno.com](https://aimimmuno.com/aim-immunotech-reports-third-quarter-2025-financial-results-and-highlights-continued-progress-across-pipeline-with-strategic-focus-on-pancreatic-cancer-clinical-program/?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
